Decision on general reimbursement for Yellox®

17 January 2012

The Danish Medicines Agency has completed its review of an application for general reimbursement for Yellox®. The product has been granted general reimbursement.

Yellox® is used for the treatment of inflammation after cataract surgery.

When we compare Yellox® with other similar medicines, we assess that the price of the medicine is commensurate with its therapeutic value.

The reimbursement status of Yellox® will be reassessed in connection with the regular reassessment of the reimbursement status of all medicines. Please find the Reimbursement Committee recommendation and the Danish Medicines Agency’s decision in the box to the right (in Danish only).

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.